The grass-roots market has potential. Is the opportunity for Chinese patent medicine coming?

[pharmaceutical network market analysis] under the guidance of the theory of traditional Chinese medicine, traditional Chinese medicine (TCM) is a product of the modernization of traditional Chinese medicine (TCM), which is made of Chinese herbal pieces as raw materials and in accordance with the prescribed prescription, production process and quality standards Data shows that in 2018, the terminal drug sales of China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) reached 132.2 billion yuan, of which 78.15% were chemical drugs, 21.85% were proprietary Chinese drugs, nearly 300 billion yuan From the perspective of trend, the growth rate of terminal drug sales in China's public medical institutions declined from 14.28% to 5.94% in 2014-2018 The growth rate of chemical drugs was higher than the horizontal line, while that of Chinese patent drugs was significantly lower than the horizontal line, with a growth rate of only 1.17% in 2018 In contrast to the slowing growth of terminal sales, at the 2019 national pharmaceutical economic information conference recently held, data showed that in recent years, the growth rate of proprietary Chinese medicine at the grass-roots level (Urban Community Center, township hospitals) was higher than that of public hospitals (urban public hospitals, county-level public hospitals), and the proportion at the grass-roots level increased year by year In terms of large categories of situations, Chinese patent medicine has its unique characteristics in chronic diseases such as cardiovascular and cerebrovascular diseases and common frequently occurring diseases such as respiratory system diseases, with excellent performance Its market share in each terminal is ranked in the top position From the perspective of growth rate, the sales growth of five categories of drugs for tumor diseases, urinary system diseases, nervous system diseases, facial features and pediatrics in the two terminals of urban community center and township health center in 2018 exceeded 10%, with great potential In recent years, there are many policies to encourage the development of traditional Chinese medicine, which is generally considered as a signal to improve the market of traditional Chinese medicine For example, in the 2004 version of the medical insurance catalog, there are 823 Chinese patent medicines, accounting for 44.5% of the total number of drugs in the medical insurance catalog Now in the 2019 version of the medical insurance catalog, the number of Chinese patent medicines has increased to 1321, accounting for nearly 50% of the total number of drugs in the medical insurance catalog The proportion of Chinese patent medicines is growing, and now it is basically equal to western medicine The number of ethnic medicines increased from 47 in 2004 to 93 in 2019 However, from the perspective of market data, the sales volume of Chinese patent medicine is growing slowly, which is also affected by the policy of regulating rational use of drugs For example, on July 1 this year, the national health and Health Commission issued a list of key monitoring drugs to prevent clinical drug abuse, but one of the new regulations shocked the medical community even more than drug control This regulation points out that in the future, doctors with western medicine background can only prescribe Chinese patent medicine after at least one year of systematic learning and examination of TCM professional knowledge, while doctors without systematic learning of TCM cannot prescribe Chinese patent medicine Some insiders expressed their concern that "Chinese patent medicine has lost half of its life in public hospitals!" In fact, the slow growth of sales of Chinese patent medicine is mainly due to the lack of detailed rules for implementation, and many enterprises are waiting for specific measures for the implementation of policies In the future, the Chinese patent medicine market is still slowly changing However, in the face of the frequent introduction of recent policies, enterprises should have the concept of risk dispersion, and timely adjust and enrich the product line, and actively respond With the development speed of grass-roots market increasing, pharmaceutical enterprises can also focus on developing grass-roots market The future market can be seen We should believe that under the supervision of the state, the industry will develop more and more in a healthy, reasonable and orderly direction The darkness is about to pass, and the dawn is ahead.